Nuclear medicine industry expert Buurlage joins SHINE
SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations. Mr. Buurlage will oversee all of SHINE’s activities in Europe, including the company’s siting, construction and operation of a medical isotope production facility there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190904005577/en/
Harrie Buurlage, SHINE’s vice president, European operations (Photo: Business Wire)
Mr. Buurlage brings more than 25 years of experience in the nuclear medicine industry to his new role at SHINE, including positions in management, operations, and sales and marketing.
Mr. Buurlage was chief operating officer and then managing director of NRG, an international nuclear service provider, in the Netherlands. Among other things, Mr. Buurlage oversaw the operation of all of NRG’s nuclear installations, including the Dutch High Flux medical isotope production facility in Petten, which produces isotopes used in more than 30,000 patient treatments a day. He led a multi-year transition of the company from a science institute to a more robust health care organization.
Before joining NRG, Mr. Buurlage was global director of manufacturing for Covidien USA, now Curium Pharma, where he was responsible for radiopharmaceutical isotope manufacturing and distribution at facilities in the Netherlands, United Kingdom and United States. Mr. Buurlage oversaw the addition of a new reactor to Covidien’s supply chain in only nine months. He also drove logistical improvements in Europe, the Middle East and Africa, and was global chairman of the company’s nuclear medicine council.
Earlier in this career, Mr. Buurlage spent nearly 15 years at Mallinckrodt, where he served in positions of increasing responsibility at Petten, including managing director of Mallinckrodt Medical (MM) B.V. and director of EMEA operations.
“It is well known that current European producers of medical isotopes are planning to cease operations in the next several years, and SHINE is excited to be in a position to ensure that Europeans have uninterrupted access to the life-saving products our team and technology can provide,” said Greg Piefer, founder and CEO of SHINE. “Harrie’s experience in the nuclear industry and European market, and his management, operations and logistics expertise will be invaluable to SHINE as we execute our plan there. We look forward to working with Harrie to make a SHINE European presence a reality, and provide for a robust European and global supply chain.”
Mr. Buurlage studied applied physics at the University of Groningen. He earned certification as a radiation safety officer at the University of Leiden, the highest-level certification of its kind in Europe, which allows holders to supervise large, complex nuclear sites.
“The company’s accelerator technology, talented team and vision for Europe, the United States and the rest of the world are incredibly compelling,” Mr. Buurlage said. “I know the European market well and am confident that SHINE will play a significant role here and in the global market, particularly because of its safer, cleaner and more cost-effective production process.”
About Medical Isotopes
Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium 99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and to stage cases of cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce a variety of medical isotopes, including Mo‑99. Roughly one percent of all Mo-99 in the world decays every hour, meaning it must be produced continuously. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.
About SHINE Medical Technologies LLC
Founded in 2010, SHINE is a development-stage company working to become a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies. It does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated that SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo-99. In 2016, SHINE received regulatory approval from the Nuclear Regulatory Commission to construct its production facility. The company began construction of the facility in the spring of 2019. Learn more at https://shinemed.com.
Director, Marketing & Corporate Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL BitHarp Extends 3 Plus 1 Offer for Mining Rigs22.10.2019 23:52:00 CEST | Press release
Business Wire requests that press release NewsItemID 20191001005793 (issued Oct. 1, 2019) “BitHarp Extends 3 Plus 1 Offer for Mining Rigs” be removed. Contact information Business Wire, New York 212-752-9600
NIKE, Inc. Announces Board Member John Donahoe Will Succeed Mark Parker as President & CEO in 2020; Parker to Become Executive Chairman22.10.2019 20:10:00 CEST | Press release
The Board of Directors of NIKE, Inc. (NYSE:NKE) announced today that John Donahoe will be appointed as the company’s new President and Chief Executive Officer, effective Jan. 13, 2020. At the same time, Mark Parker, CEO since 2006 and Chairman, President & CEO since 2016, will become Executive Chairman and continue to lead the Board of Directors and work closely with Donahoe and the senior management team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191022006118/en/ NIKE, Inc. announces Board Member John Donahoe (right) will succeed Mark Parker (left) as President & CEO in 2020; Parker to become Executive Chairman (Photo: Business Wire) “This is an exciting time for Nike where we see brand strength and momentum throughout the world and great opportunity for future growth,” said Parker. “I am delighted John will join our team. His expertise in digital commerce, technology, global strategy and leadership combined with his s
Schlumberger Announces Senior Notes Redemption22.10.2019 20:05:00 CEST | Press release
Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of Schlumberger (“SHC”), will redeem the entire outstanding principal amount of its 3.000% Senior Notes due 2020 (the “2020 Notes”), and that Cameron International Corporation, an indirect wholly-owned subsidiary of Schlumberger (“Cameron”), will redeem the entire outstanding principal amount of its 4.50% Senior Notes due 2021 (the “2021 Notes”) and the entire outstanding principal amount of its 3.60% Senior Notes due 2022 (the “2022 Notes” and, collectively with the 2020 Notes and the 2021 Notes, the “Notes”). The redemption date for each series of Notes is November 21, 2019 (the “Redemption Date”). The aggregate principal amount of the 2020 Notes outstanding is $416,044,000, the aggregate principal amount of the 2021 Notes outstanding is $126,193,000 and the aggregate principal amount of the 2022 Notes outstanding is $105,779,000. The Notes will be redeeme
CES Unveiled in Paris Highlights Emerging Tech and Artificial Intelligence22.10.2019 18:04:00 CEST | Press release
The Consumer Technology Association (CTA) ® today made several announcements at CES Unveiled in Paris, an official CES® 2020 preview event. Executives, influential media and prominent industry influencers gathered to celebrate the latest European innovations and experience a preview of CES 2020. As part of wider updates ahead of CES 2020, CTA announced that Daimler’s Ola Källenius, Chairman of the Board of Management of Daimler AG & Head of Mercedes-Benz Cars, will give a CES 2020 keynote on Monday, Jan. 6 at 8:30 PM at the Park Theater at the Park MGM Hotel in Las Vegas, NV. The event, which showcased leaders in artificial intelligence (AI) technologies, allowed attendees to see and interact with the latest innovations in AI through exhibitor displays and conference programming. AI technologies will feature prominently at CES 2020 where it will be core to solutions such as smart cities, sports tech and digital health. CTA also recognized 33 French companies announced as CES 2020 Innov
Union Acquisition Corp. II Announces Closing of $200 Million Initial Public Offering22.10.2019 17:47:00 CEST | Press release
Union Acquisition Corp. II (NASDAQ: LATNU) (the “Company”) announced today that it closed its initial public offering of 20,000,000 units, including 2,500,000 units subject to the underwriters’ over-allotment option, at $10.00 per unit. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company’s units began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “LATNU” on October 18, 2019. Each unit consists of one ordinary and one redeemable warrant with each warrant entitling the holder to purchase one ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be traded on Nasdaq under the symbols “LATN” and “LATNW”, respectively. Cantor Fitzgerald & Co. acted as the sole book-running manager of the offering. EXOS Securities, LLC and Arcadia Securities, LLC acted as co-managers. Of the proceeds received from the consummation of the
TeleSign Expands Global Services through Partnership with Proximus22.10.2019 16:00:00 CEST | Press release
TeleSign, a leader in authentication and communication services, a wholly-owned subsidiary of BICS, today announced a new partnership with Proximus, the largest telecommunications company in Belgium. This partnership will provide TeleSign’s fraud risk product portfolio to provide regional and international companies with a presence in Belgium. As the mobile identity ecosystem continues to rapidly evolve globally, it is more important than ever that businesses ensure the strongest authentication and verification measures to secure end-user accounts and prevent fraud, especially in the financial sector. According to PwC, almost two-thirds (65 percent) of companies in Belgium experienced economic crime in the last two years, compared to under half (49 percent) globally. Fraud such as account take over (ATO) through SIM swap and porting attacks can be significantly expensive to both end users and businesses. With the strength of Proximus’ insights and TeleSign’s expertise, this partnership